Primary CNS lymphoma: update on molecular pathogenesis and therapy.
Primary CNS lymphoma: update on molecular pathogenesis and therapy.
复制标题
原发性中枢神经系统淋巴瘤：分子发病机制和治疗的最新进展。
DOI：
10.1080/10428194.2022.2133541
复制
发表时间：
2023
影响因子：
2.6
通讯作者：
Rubenstein,JamesL
中科院分区：
文献类型：
--
作者：
Mo,ShirleyS;Cleveland,Joseph;Rubenstein,JamesL
原发性中枢神经系统淋巴瘤 (PCNSL) 是一种罕见且具有侵袭性的结外非霍奇金淋巴瘤，作为一种脑肿瘤，给诊断和治疗带来了一系列独特的挑战。随着新一代测序的出现，我们回顾了对其分子和基因组发病机制的了解的最新进展。我们还强调管理中的关键问题，重点关注新兴技术和新生物疗法，包括单克隆抗体、IMiD、BTK 抑制剂、PD-1 抑制剂和 CAR-T 疗法。这些方法的整合可能会增强诱导和巩固策略，以抑制 NF-κB 激活和抗肿瘤免疫反应，同时最大限度地减少基因毒性方法的有害影响。
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extra-nodal non-Hodgkin lymphoma that as a brain tumor poses a unique set of challenges in diagnosis and management. With the advent of next-generation sequencing, we review updates in the understanding of its molecular and genomic pathogenesis. We also highlight key issues in management, with a focus on emerging technologies and new biological therapies including monoclonal antibodies, IMiDs, BTK inhibitors, PD-1 inhibitors, and CAR-T therapy. Integration of these approaches will likely enhance induction and consolidation strategies to suppress NF-κB activation and the anti-tumor immune response, while minimizing the often noxious effects of genotoxic approaches.